共 530 条
[21]
Martin PJ(2016)Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study Int J Hematol 103 243-1810
[22]
Rizzo JD(2020)A phase 3 randomized study of remestemcel-L versus placebo added to second-line therapy in patients with steroid-refractory acute graft-versus-host disease Biol Blood Marrow Transplant 26 835-10
[23]
Wingard JR(2020)A phase I study to evaluate two doses of Wharton’s jelly-derived mesenchymal stromal cells for the treatment of de novo high-risk or steroid-refractory acute graft versus host disease Stem Cell Rev Rep 16 979-2927
[24]
Ballen K(2020)The development of ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease Blood Adv 4 3789-1182
[25]
Curtin PT(2020)Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease New Engl J Med 382 1800-3962
[26]
Cutler C(2016)International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium Biol Blood Marrow Transplant 22 4-S173
[27]
Litzow MR(2022)Comparable long-term outcomes between upfront haploidentical and identical sibling donor transplant in aplastic anemia: a national registry-based study Haematologica 107 2918-297
[28]
Nieto Y(2014)Total body irradiation and cyclophosphamide plus antithymocyte globulin regimen is well tolerated and promotes stable engraftment as a preparative regimen before T cell-replete haploidentical transplantation for acute leukemia Biol Blood Marrow Transplant 20 1176-265
[29]
Savani BN(2015)Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study Blood 125 3956-936
[30]
Schriber JR(2018)Incidence, risk factors, microbiology and outcomes of pre-engraftment bloodstream infection after haploidentical hematopoietic stem cell transplantation and comparison with HLA-identical sibling transplantation Clin Infect Dis 67 S162-401